GlassScriptPhysician profile
Alexander Blake Hardwick
NPI 1780050385
$1,901.14
in general payments reported to CMS, 2019-2025
22 companies · $351 in 2025
The $351 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $633 · 2022: $777 · 2023: $119 · 2024: $22.23 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $492.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $379.49 | 2021-2025 | |
| Amgen INC. | $202.69 | 2021-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $176.83 | 2021-2023 | Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $132.55 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.75 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $117.80 | 2021-2022 | |
| Boston Scientific Corporation | $110.93 | 2021-2025 | Bodyguardian |
| Alnylam Pharmaceuticals INC. | $109.67 | 2022-2025 | Amvuttra |
| Amarin Pharma, INC. | $100.01 | 2021-2022 | |
| Irhythm Technologies, INC. | $96.51 | 2022-2023 | Zio Xt Patch |
| Merck Sharp & Dohme LLC | $59.30 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $48.41 | 2022-2023 | Eliquis |
| Cleerly, INC. | $48.00 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Heartflow, INC. | $29.80 | 2025 | |
| Glaxosmithkline, LLC. | $28.18 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $23.76 | 2021 | |
| Baxter Healthcare | $22.23 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Pfizer INC. | $22.02 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $21.78 | 2022 | |
| Scpharmaceuticals INC. | $17.43 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $13.75 | 2021 | |
| Medtronic, INC. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Hardwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.